Prosight Management’s CareDx CDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-250,000
Closed -$4.71M 49
2025
Q4
$4.71M Sell
250,000
-254,030
-50% -$4.26M 0.97% 27
2025
Q3
$7.33M Buy
504,030
+201,222
+66% +$2.87M 1.71% 23
2025
Q2
$5.92M Buy
302,808
+166,215
+122% +$2.95M 1.44% 23
2025
Q1
$2.42M Buy
136,593
+56,593
+71% +$1.22M 0.8% 28
2024
Q4
$1.71M Buy
+80,000
New +$1.95M 0.47% 31

Other funds holding CDNA

Prosight Management's CDNA Position: Q1 2026 in Review

Prosight Management sold out of CareDx (CDNA) in Q1 2026, closing a stake of 250,000 shares — an estimated $4.71M sold.

Prosight Management first reported a position in CDNA in Q4 2024 and held it in 5 quarters. The position peaked at $7.33M in Q3 2025. 191 funds tracked by Wall St. Rank hold CDNA as of Q1 2026.

  • Prosight Management reported no remaining CareDx position as of Q1 2026 after selling out during the quarter.
  • Prosight Management sold 250,000 CareDx shares in Q1 2026, an estimated $4.71M.
  • Prosight Management first reported a position in CareDx in Q4 2024 and held it in 5 quarters.
  • Prosight Management's CareDx position peaked at $7.33M in Q3 2025.
  • 191 funds tracked by Wall St. Rank held CareDx as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.